Principal Financial Group Inc. Has $38.19 Million Position in Hims & Hers Health, Inc. $HIMS

Principal Financial Group Inc. boosted its stake in shares of Hims & Hers Health, Inc. (NYSE:HIMS) by 9.0% in the third quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 673,213 shares of the company’s stock after purchasing an additional 55,315 shares during the quarter. Principal Financial Group Inc.’s holdings in Hims & Hers Health were worth $38,185,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also modified their holdings of the company. Quent Capital LLC bought a new position in Hims & Hers Health in the 3rd quarter worth $28,000. Virtus Advisers LLC acquired a new stake in Hims & Hers Health in the 2nd quarter valued at approximately $26,000. Quaker Wealth Management LLC bought a new position in Hims & Hers Health in the 2nd quarter worth approximately $29,000. Bessemer Group Inc. lifted its holdings in shares of Hims & Hers Health by 105.8% during the second quarter. Bessemer Group Inc. now owns 607 shares of the company’s stock worth $30,000 after buying an additional 312 shares during the last quarter. Finally, Hilltop National Bank acquired a new stake in shares of Hims & Hers Health in the third quarter worth $35,000. 63.52% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities analysts recently commented on the stock. Wall Street Zen cut shares of Hims & Hers Health from a “hold” rating to a “sell” rating in a research note on Saturday, November 8th. Barclays started coverage on shares of Hims & Hers Health in a report on Monday, December 8th. They set an “overweight” rating and a $48.00 price objective on the stock. Zacks Research cut shares of Hims & Hers Health from a “hold” rating to a “strong sell” rating in a research note on Monday, January 19th. Weiss Ratings restated a “hold (c)” rating on shares of Hims & Hers Health in a research note on Monday, December 29th. Finally, Evercore ISI assumed coverage on Hims & Hers Health in a report on Monday, January 12th. They issued an “in-line” rating and a $33.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, nine have assigned a Hold rating and four have assigned a Sell rating to the company. According to MarketBeat, Hims & Hers Health has an average rating of “Hold” and a consensus target price of $42.62.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims launched a compounded oral semaglutide pill priced at an introductory $49/month (followed by a subscription plan), an aggressive price point that could expand patient access and drive new subscription revenue if distribution holds. Exclusive: Hims and Hers Health launches copy of Wegovy pill at $49
• Positive Sentiment: Hims added a multi‑cancer early detection test (Galleri) to its offerings, widening its mix beyond prescriptions into preventive care and potential recurring testing revenue. Hims & Hers Launches Multi-Cancer Early Detection Testing
• Neutral Sentiment: Initial market reaction was mixed: the $49 announcement briefly pressured major GLP‑1 drugmakers while lifting HIMS sentiment, illustrating the market’s sensitivity to cheap oral offerings even though compounded prescriptions remain a small share of total GLP‑1 demand. Novo Nordisk and Eli Lilly fall after Hims & Hers announce $49 copy of Wegovy pill
• Negative Sentiment: Novo Nordisk has publicly accused Hims of “illegal mass compounding,” called the product unsafe, and said it will pursue legal action — creating immediate litigation risk, potential injunctions, and costly disputes that could curb or halt Hims’s selling strategy. Novo Nordisk to take legal action against Hims & Hers for Wegovy compounding
• Negative Sentiment: Regulatory scrutiny may intensify — reports cite the FDA and industry voices flagging possible enforcement or safety reviews; that uncertainty is weighing on the stock as investors reassess execution and regulatory risk. Novo Nordisk stock climbs out of hole on FDA chief’s threat to block Hims and Hers pill

Hims & Hers Health Trading Down 3.7%

Shares of HIMS stock opened at $23.50 on Friday. The company has a debt-to-equity ratio of 1.67, a quick ratio of 1.64 and a current ratio of 1.88. The firm has a fifty day moving average of $33.30 and a 200-day moving average of $43.64. Hims & Hers Health, Inc. has a 52-week low of $22.95 and a 52-week high of $72.98. The stock has a market cap of $5.35 billion, a price-to-earnings ratio of 43.51, a P/E/G ratio of 4.02 and a beta of 2.43.

Hims & Hers Health (NYSE:HIMS) last posted its earnings results on Monday, November 3rd. The company reported $0.06 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.03). The business had revenue of $598.98 million during the quarter, compared to the consensus estimate of $578.99 million. Hims & Hers Health had a net margin of 6.05% and a return on equity of 24.67%. The business’s revenue was up 49.2% compared to the same quarter last year. During the same period in the previous year, the firm earned $0.32 EPS. On average, equities research analysts forecast that Hims & Hers Health, Inc. will post 0.29 earnings per share for the current fiscal year.

Hims & Hers Health announced that its Board of Directors has authorized a stock buyback program on Monday, November 17th that permits the company to buyback $250.00 million in outstanding shares. This buyback authorization permits the company to purchase up to 3% of its shares through open market purchases. Shares buyback programs are usually a sign that the company’s management believes its shares are undervalued.

Insider Buying and Selling

In related news, CFO Oluyemi Okupe sold 9,067 shares of the business’s stock in a transaction on Tuesday, January 20th. The stock was sold at an average price of $30.34, for a total value of $275,092.78. Following the sale, the chief financial officer owned 91,617 shares of the company’s stock, valued at $2,779,659.78. The trade was a 9.01% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Deborah M. Autor sold 7,054 shares of the stock in a transaction on Wednesday, December 17th. The stock was sold at an average price of $36.71, for a total value of $258,952.34. Following the transaction, the insider owned 6,175 shares of the company’s stock, valued at $226,684.25. This represents a 53.32% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders sold 131,974 shares of company stock worth $4,763,800. Insiders own 13.71% of the company’s stock.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.